Frontlight ResearchEarly access
Active, not recruitingPhase 3
A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
Key facts
- Who runs it
- Orchard Therapeutics
- Where
- Minneapolis, United StatesSee the siteAlso in 3 other countries, 4 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 41 people enrolled
- Started
- 11 Dec 2023
- Expected to end
- Mar 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Experimental: OTL-203
- Active Comparator: Allo-HSCT
- Record updated
- 22 December 2025
Who can take part
- Age
- 28 days to 30 months
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Norm-referenced cognitive standard score of ≥70 measured by age-appropriate cognitive domains of either Bayley Scale of Infant Development (BSID)-III or Wechsler Preschool and Primary Scale of Intelligence (WPPSI)-IV
- Confirmed laboratory diagnosis of MPS-IH as demonstrated by biallelic mutation(s) in the gene coding for IDUA enzyme
- Final confirmation of MPS-IH diagnosis by a Diagnostic Review Committee (DRC)
Who cannot take part
- Previous allo-HSCT or gene therapy
- Current enrollment or past treatment in any other interventional study/trial using a novel investigational agent and/or treated with prohibited medications listed in the protocol
- Positivity to serological testing for Human Immunodeficiency Virus (HIV)-1 or HIV-2, Human T Lymphotropic Virus (HTLV)-1 or HTLV-2, Hepatitis B Virus (HBV) core, Hepatitis C Virus (HCV), mycoplasma, active tuberculosis (TB) and not meeting the microbiology biological screening requirements
- Malignant neoplasia (except local skin cancer)
- Myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
- History of uncontrolled seizures
- Subjects with an active infection not responsive to treatment, end-organ damage, or any other disease that contraindicates performance of any of the procedures detailed in the protocol, or medical conditions or extenuating circumstances that, in the opinion of the Investigator, might compromise the subject's well-being or safety, or the interpretability of the subject's clinical data
- Subjects, who in the opinion of the Investigator, may not be able to comply with protocol requirements or cooperate fully with the study procedures and necessary long-term follow up
Where in United States
Also in 3 other countries, 4 sites
- University of Minnesota, PediatricsMinneapolis, United States
About the trial
What the trial wants to find out
A multi-center randomized clinical trial to compare OTL-203 (gene therapy) with stem cell transplant (standard of care) in patients with MPS-IH (Hurler syndrome).
The 2 groups in the trial
- OTL-203Treatment being tested
Eligible subjects randomized to Arm 1 will receive an intravenous (IV) infusion of OTL-203 gene therapy. Subjects will receive conditioning regimen with busulfan and fludarabine prior to OTL-203 infusion.
Treatment: Experimental: OTL-203
- Allo-HSCTExisting treatment, for comparison
Eligible subjects randomized to Arm 2 will receive allogeneic hematopoietic stem cell transplantation. Subjects will receive conditioning regimen with busulfan and fludarabine prior to allo-HSCT.
Treatment: Active Comparator: Allo-HSCT
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Active Controlled Clinical Trial to Evaluate the Efficacy and Safety of OTL-203 in Subjects With Mucopolysaccharidosis Type I, Hurler Syndrome (MPS-IH) Compared to Standard of Care With Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
- Record updated
- 22 December 2025